These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30975913)

  • 21. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
    DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
    Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.
    Kagiyama Y; Kitaura J; Togami K; Uchida T; Inoue D; Matsukawa T; Izawa K; Kawabata KC; Komeno Y; Oki T; Nakahara F; Sato K; Aburatani H; Kitamura T
    Int J Hematol; 2012 Nov; 96(5):638-48. PubMed ID: 23097187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Lin S; Ptasinska A; Chen X; Shrestha M; Assi SA; Chin PS; Imperato MR; Aronow BJ; Zhang J; Weirauch MT; Bonifer C; Mulloy JC
    Blood; 2017 Sep; 130(10):1213-1222. PubMed ID: 28710059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.
    Mulloy JC; Cammenga J; MacKenzie KL; Berguido FJ; Moore MA; Nimer SD
    Blood; 2002 Jan; 99(1):15-23. PubMed ID: 11756147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
    Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
    Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between AML1-ETO and MLL-AF9 fusion gene expressions and hematological parameters in acute myeloid leukemia.
    Muddathir ARM; Hamid TAM; Mohamed Elamin E; Khabour OF
    Gulf J Oncolog; 2020 Sep; 1(34):65-69. PubMed ID: 33431365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
    Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
    Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia.
    Duque-Afonso J; Veratti P; Rehman UU; Herzog H; Mitschke J; Greve G; Eble J; Berberich B; Thomas J; Pantic M; Waterhouse M; Gentile G; Heidenreich O; Miething C; Lübbert M
    Int J Cancer; 2024 Dec; 155(11):2068-2079. PubMed ID: 39146497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
    Tian Y; Wang G; Hu Q; Xiao X; Chen S
    J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.
    Higuchi M; O'Brien D; Kumaravelu P; Lenny N; Yeoh EJ; Downing JR
    Cancer Cell; 2002 Feb; 1(1):63-74. PubMed ID: 12086889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Wang Y; Liu Y; Xu Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.
    Martin-Padura I; Marighetti P; Gregato G; Agliano A; Malazzi O; Mancuso P; Pruneri G; Viale A; Bertolini F
    Neoplasia; 2012 Nov; 14(11):1057-66. PubMed ID: 23226099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.
    Zhou F; Liu Y; Rohde C; Pauli C; Gerloff D; Köhn M; Misiak D; Bäumer N; Cui C; Göllner S; Oellerich T; Serve H; Garcia-Cuellar MP; Slany R; Maciejewski JP; Przychodzen B; Seliger B; Klein HU; Bartenhagen C; Berdel WE; Dugas M; Taketo MM; Farouq D; Schwartz S; Regev A; Hébert J; Sauvageau G; Pabst C; Hüttelmaier S; Müller-Tidow C
    Nat Cell Biol; 2017 Jul; 19(7):844-855. PubMed ID: 28650479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
    Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dominant negative effects of the AML1/ETO fusion oncoprotein.
    Fenske TS; Pengue G; Graubert TA
    Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells.
    Saia M; Termanini A; Rizzi N; Mazza M; Barbieri E; Valli D; Ciana P; Gruszka AM; Alcalay M
    Sci Rep; 2016 Oct; 6():34957. PubMed ID: 27713544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.